Biography

Prof. Xin Zhou is from the Cancer Research Institute of Jilin University and the Institute of Translational Medicine, The First Hospital of Jilin University. He obtained his bachelor's degree from the School of Pharmaceutical Sciences at Jilin University in 2008 and his PhD from the Institutes of Biomedical Sciences at Fudan University in 2013, advised by Professor Kun-Liang Guan, Professor Yue Xiong, and Professor Qun-Ying Lei. After his postdoctoral training at the MD Anderson Cancer Center at the University of Texas in 2020, he joined the Cancer Research Institute of Jilin University as an associate professor and Ph.D. supervisor. In 2022, He has been promoted to be a "Tang Aoqing " professor at Jilin University. His main research interest is in the dysregulated metabolism homeostasis in human diseases, especially in cancer. He has co-authored numerous original research articles in prestigious academic journals such as Journal of Clinical Investigation, Journal of Experimental Medicine, eLife, Biochemical Journal, Cancer Cell, Nature Genetics, and Molecular Cell. He has also been invited to write reviews for journals such as Protein & Cell, Current Pharmaceutical Design, Acta., Biochim. Biophys. Sin (Shanghai). He was the winner of the second prize of the Natural Science Award from the Ministry of Education. Currently, he serves as a youth council member of the Chinese Biophysical Society’s Academic Subgroup of Metabolic Biology, a council member of the Jilin Provincial Society for Cell Biology, a member of the Pharmacology Committee of the Jilin Provincial Pharmaceutical Association, and an executive member of editorial board of the Electronic Journal of Metabolism and Nutrition of Cancer.

Education

2013  Ph.D., Biochemistry and Molecular Biology, Institutes of Biomedical Sciences, Fudan University

          Supervisor: Kun-Liang Guan, Yue Xiong, and Qun-Ying Lei

2008  B.S., Bioengineering (medicine), School of Pharmaceutical Sciences, Jilin University

Positions

2022- Professor, Cancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, P.R. China

2020-2021  Associate Professor, Cancer Research Institute of Jilin University, The First Hospital of Jilin University, Changchun, P.R. China

2019-2020 Research Scientist, Department of Cancer Biology, MD Anderson Cancer Center, University of Texas, Huston, U.S.

2014-2019 Postdoctoral Fellow, Department of Cancer Biology, MD Anderson Cancer Center, University of Texas, Huston, U.S.

Professional Membership

Youth council member of the Chinese Biophysical Society’s Academic Subgroup of Metabolic Biology (2021-)

Council member of the Jilin Provincial Society for Cell Biology (2021-)

Member of the Pharmacology Committee of the Jilin Provincial Pharmaceutical Association (2020-)

Awards/Honors

2017  Caroline Ross Fellowship

2015  The Second Prize of the Natural Science Award for Excellent Scientific Research

          Achievement (Science and Technology) from the Ministry of Education

2008  Outstanding Graduates of Jilin University in 2008

2008  Outstanding Undergraduate Thesis of Jilin University in 2008

Professional Service

Executive member of editorial board of the Electronic Journal of Metabolism and Nutrition of Cancer (2021-)Ÿ

Research Interest

Dysregulated metabolism homeostasis in cancer microenvironment

1. Metabolic reprograming and metabolite sensing

2. Metabolic checkpoint in cancer immunotherapy

3. Metabolism dysregulation and drug resistance in cancer

Selected Publications

Co-authored numerous original research articles in prestigious academic journals such as Journal of Clinical Investigation, Journal of Experimental Medicine, eLife, Biochemical Journal, Cancer Cell, Nature Genetics, and Molecular Cell.

Total citations: > 1900 - H-index = 17 (Web of Knowledge)

1. Zhou Xin, He Chenxi, Ren Jiangong, Dai Congxin, Stevens R. Sharon, Wang Qianghu, Zamler Daniel, Shingu Takashi, Yuan Liang, Chandregowda R. Chythra, Wang Yunfei, Ravikumar Visweswaran, Rao U.K. Arvind, Zhou Feng, Zheng Hongwu, Rasband N. Matthew, Chen Yiwen, Lan Fei, Heimberger B. Amy, Segal M. Benjamin, Hu Jian^*. Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα–mediated lipid metabolism, J Clin Invest. 2020, 130(5):2220-36. (Cover story)

2. Zhou Xin^#, Shin Seula^#, He Chenxi^#, Zhang Qiang, Rasband N. Matthew, Ren Jiangong, Dai Congxin, Zorrilla-Veloz I. Rocío, Shingu Takashi, Yuan Liang, Wang Yunfei, Chen Yiwen, Lan Fei, Hu Jian^*.Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis, Elife, 2021, 10:e60467. (^# Contribute equally)

3. Ren Jiangong^#, Dai Congxin^#, Zhou Xin^#, Barnes A. Joseph, Chen Xi, Wang Yunfei, Yuan Liang, Shingu Takashi, Heimberger B. Amy, Chen Yiwen, Hu Jian^*.Qki is an essential regulator of microglial phagocytosis in demyelination, J Exp Med.2021, 218(1):e20190348. (^# Contribute equally)

4. Zhou Xin#, Wang Shuyang#, Wang Zhen, Feng Xu, Liu Peng, Lv Xian-Bo, Li Fulong, Yu Fa-Xing, Sun Yiping, Yuan Haixin, Zhu Hongguang, Xiong Yue*, Lei Qun-Ying*, Guan Kun-Liang*.Estrogen regulates Hippo signaling via GPER in breast cancer, J Clin Invest. 2015, 125(5), 2123-35. (# Contribute equally)

5. Zhou Xin, Li Ting-Ting, Feng Xu, Hsiang Esther, Xiong Yue, Guan Kun-Liang, Lei Qun-Ying*.Targeted polyubiquitylation of RASSF1C by the Mule and SCFβ-TrCP ligases in response to DNA damage, Biochem J. 2012, 441(1), 227-36.

6. Zhou Xin*, Lei Qun-Ying*.Regulation of TAZ in Cancer, Protein Cell. 2016, 7(8), 548-61. (* Corresponding author)

7. Zhou Xin#, Wang Zhen#, Huang Wei, Lei Qun-Ying*.G protein-coupled receptors: bridging the gap from the extracellular signals to the Hippo pathway, Acta Biochim Biophys Sin (Shanghai). 2015, 47(1), 10-5. (# Contribute equally)

8. Yao Chuan-Bo#, Zhou Xin#, Chen Ce-Shi, Lei Qun-Ying*. The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer,Yi Chuan. 2017, 39(7), 617-29. (# Contribute equally)

9. Lin Ruiting#, Zhou Xin#, Huang Wei#, Zhao Di, Lv Lei, Xiong Yue, Guan Kun-Liang, Lei Qun-Ying*.Acetylation control of cancer cell metabolism, Curr Pharm Des. 2014, 20(15), 2627-33. (# Contribute equally)

10. Xuelian Liu, Yu Zhang, Wei Li*, Xin Zhou*.Lactylation, an emerging hallmark of metabolic reprogramming: Current progress and open challenges, Front Cell Dev Biol. 2022, 10:972020.

Projects

2022.01-2024.12 Study of role and mechanism of QKI in regulating cholesterol metabolism in glioma，Key program in free exploration category of Science and Technology Agency of Jilin Province, 0.2 million (RMB)

2021.07-2024.06  Study of secondary development of the preventive and therapeutic effects of ShenYi Capsule on liver carcinogenesis based on cancer metabolism and microenvironment, Special project for the development of pharmaceutical and healthcare industry of Science and Technology Agency of Jilin Province, 0.9 million (RMB)

2021.01-2023.12  Study of role and mechanism of Monocarboxylate transporter 4 in mediating AMPK-induced lactate metabolic reprogramming in lung cancer, National Natural Science Foundation of China for Youth Scholar, 0.24 million (RMB)